GMTX - Arcus Bio ranks in top weekly healthcare gainers amid positive domvanalimab data; Biogen hit by Lilly donanemab Breakthrough Therapy tag
JuSun/iStock via Getty Images During the week ended June 25, 2021, Healthcare sector rose 2.01% and Healthcare Select Sector SPDR ETF (XLV) gained 1.58% compared to weekly gain of 2.82% of S&P 500 ETF. Leading the top gainers pack was Atossa Therapeutics (ATOS) which surged ~61.1% over the past week. The stock continued its two-weeks winning streak amid a series of catalysts. Read more: Quant System Highlight: Investors Following This Are Up 120% In A Month! Arcus Biosciences (RCUS) gained ~25% after the company reported positive data from data from domvanalimab-based combinations studies in lung cancer. Also, RCUS draws buy rating from BTIG on the upcoming milestone. Translate Bio (TBIO) advanced ~24.7% following the launch of Phase 1 trial of mRNA influenza vaccine. However, analysts are of opinion that CureVac's underwhelming COVID-19 vaccine data could foretell trouble for Translate Bio. BeiGene (BGNE) rose ~12.9% amid series of approvals for drug candidates in China over past two weeks. On June 23, BeiGene's tislelizumab OK'd in China
For further details see:
Arcus Bio ranks in top weekly healthcare gainers amid positive domvanalimab data; Biogen hit by Lilly donanemab Breakthrough Therapy tag